NewsEvents

Your Yourlocation: Home > Tiotropium bromide(136310-93-5) plus odatroxel FDC can provide additional lung function and quality of life

TONADO ™ study 1 data was first published at the European Society of Respiratory Society (ERS) 2014 International Conference. The study, which lasted for 52 weeks, included more than 5,000 patients with chronic obstructive pulmonary disease, and the results of the study have also been incorporated into the recent study of tiotropium bromide(136310-93-5) plus oxodilapine FDC as a chronic obstructive pulmonary maintenance program to Europe and US drug regulatory authorities to submit the application for registration materials.

The results of the study show that tiotropium bromide(136310-93-5) plus odatroxel FDC can provide additional lung function and quality of life benefit for patients compared with tiotropium and odatrox monotherapy. Based on the additional benefit of the significant benefit of the Sliverine® active tiotroponium bromide, there is more in the tiotropium bromide plus da Dortroon® FDC treatment group Patients are expected to be able to return to a more independent state of life.

Chronic obstructive pulmonary disease is a chronic disease that involves about 65 million patients worldwide. Slowly blocked lungs can cause a heavy burden on patients and are one of the major causes of death worldwide. Siu Lihua ® (tiotropium bromide(136310-93-5)) is the world's largest prescription of chronic obstructive pulmonary maintenance therapy drugs, with difficult to surpass the real world clinical experience and clear efficacy and safety characteristics, which received more than 230 studies Results support. Striverdi® is a fast-acting and long-acting bronchodilator (LABA) that is administered once a day. Oditro was specially developed as a preferred combination of tiotropium bromide (Si Lihua ®).

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved